Position in NVS
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$315,477
+$7,992 QoQ
Shares Held
2,013
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
#1,104
of 1,603 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Greykasell Wealth Strategies, Inc. holds $4,734,430 across 12 Drug Manufacturers - General names. NVS ranks #5 (6.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
5,664 | $1,425,288 | |
| 2 | AMGN |
Amgen Inc
|
3,119 | $1,129,452 | |
| 3 | JNJ |
Johnson & Johnson
|
3,163 | $803,307 | |
| 4 | LLY |
ELI LILLY & Co
|
381 | $456,982 | |
| 5 | NVS |
Novartis AG
This page
|
2,013 | $315,477 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
1,622 | $204,923 | |
| 7 | AZN |
Astrazeneca PLC
|
690 | $130,837 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
1,848 | $106,481 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $315,477 | 2,013 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $307,485 | 2,013 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $277,532 | 2,013 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $258,147 | 2,013 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $243,593 | 2,013 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $224,409 | 2,013 | Shares | Sole | 2025-05-09 | |
| No filing history on record for this holder in this stock. | ||||||